BOTULINUM TOXIN-A – THE EXPERIENCE OF UROLOGICAL TUBERCULOSIS PATIENTS TREATMENT
Abstract
Are presented the results of intravesical botulinum toxin-A injections (Neuronox®) in 16 patients with tuberculosis of the urinary tract with lower urinary tract symptoms, which despite taking four anti-TB drugs for 3–4 months, and trospium chloride antiholinolitiс therapy during one month, there was no increase in the bladder capacity. The patients daily frequency of urination amounted to 32,8 ± 2,7 times. Functional bladder capacity was 56,0 ± 9,3 ml. QоL index was 5,40 ± 0,13. I-PSS score was 30 ± 1,6. Evaluating the effectiveness of treatment after 4 weeks showed that the frequency of urination decreased to 10,0 ± 0,3 times a day, functional bladder capacity increased to 196,0 ± 28,8 ml. Positive dynamics is reflected in the results of tests assessing urinary tract symptoms and quality of life. Index I-PSS was 10,6 ± 0,9 and QоL – 2,20 ± 0,11. Residual urine in any case was not observed. 12 patients surveyed in a year exceed the bladder capacity of 200 ml, and the frequency of urination at night did not exceed 8–10.
Obtained preliminary data showed a pronounced clinical effect of intravesical injection of botulinum toxin A (Neuronox®) and improving the quality of life of patients with tuberculosis of the urinary tract after failure of previously conducted antiholinolitiс therapy in patients receiving anti-TB drugs. During intravesical injection of botulinum toxin A pronounced complications and adverse reactions not observed.
About the Authors
M. N. TyllashaykhovUzbekistan
Z. R. Rashidov
Uzbekistan
S. K. Alydzhanov
Russian Federation
References
1. Даренков А.Ф., Балчий-Оол Д.К. Рефлексотерапия цисталгии // Урол. и нефрол. – 1982. – № 1. – С. 32-37.
2. Камышан И.С., Погребинский В.М. Туберкулез мочевых органов. – Киев: Здоровье, 1987. – 197 с.
3. Кульчавеня Е.В. Посттуберкулезная цисталгия // Урол. и нефрол. – 1995. – № 4. – С. 47-50.
4. Кульчавеня Е.В., Брижатюк Е.В. Туберкулез мочевого пузыря: диагностика и лечение // Урология. – 2006. – № 3. – С. 61-66.
5. Лосев Н.А., Новиков А.И., Вахмистрова Т.И. Патогенез и лечение нейрогенной дисфункции мочевого пузыря при нефротуберкулезе // Материалы 11-го Всерос. съезда врачей-фтизиатров. – СПб., 1992. – С. 195.
6. Начанкар Р.К. Туберкулез мочевого пузыря. // Урол. и нефрол. – 1985. – № 5. – С. 16-18.
7. Пушкарь Д.Ю. Гиперактивный мочевой пузырь у женщин. – М.: МЕД пресс-информ, 2003. – 160 с.
8. Соловьева И.П. Патологическая анатомия туберкулеза мочеполовой системы // Туберкулез мочеполовой системы: рук-во для врачей / под ред. Т.П. Мочаловой. – М.: Медицина, 1993. – С. 26-39.
9. Тарасенко Л.Ю., Одинец В.С., Уртенов Р.Х. Применение М-холиноблокаторов в комплексной терапии туберкулеза мочевого пузыря // Туберкулез в России – год 2007: материалы Российского съезда фтизиатров. – Москва, 2007. – С. 334-335.
10. Ягафарова Р.К., Вахмистрова Т.И. Туберкулез почек, мочеточников и мочевого пузыря // Внелегочный туберкулез / под ред. А.В. Васильева – СПб., 2002. – С. 276-289.
11. Guzman S., Honeck P., Weiss J. et al. Botulinum toxin injection for neurogenic and no neurogenic bladder dysfunction // Arch. Esp. Urol. – 2005. – Vol. 58. – N. 7. – P. 651-655.
12. Hikita K., Honda M., Kawamoto B., et al. Botulinum toxin type A injection for neurogenic detrusor overactivity: clinical outcome in Japanese patients // Int. J. of Urology. – 2013. – Vol. 20. – N. 1. – P. 94-99.
13. Ho M.H., Lin L.L., Haessler A.L., Bhatia N.N. Intravesical injection of botulinum toxin for the treatment of overactive bladder // Curr. Opin. Obstet. Gynecol. – 2005. – Vol. 17. – N. 5. – P. 512-518.
14. Karsenty G, Corcos J, Schurch B. Urological applications of botulinum toxins // Prog. Urol. – 2006. – Vol. 16. – N. 3. – P. 263-274.
15. McAleer S.J., Johnson C.W., Johnson W.D. Genitourinary Tuberculosis. // Campbell-Walsh Urology. – 9th ed. / Editor-in-chief A.J. Wein; editors L.R. Kavoussi, A.C. Novick, A.W. Partin, C.A. Peters. – Philadelphia: W.B. Saunders, 2007. – P. 436-447.
16. Skutil V., Obsitnik M. Persistent tuberculosis cystitis: the most common indication for nephrectomy in the management of urogenital tuberculosis // Eur. Urol. – 1987. – Vol. 13. – N. 1–2. – P. 57-61.
17. Toozs-Hobson P., Latthe P. Critical evaluation of the efficacy and safety of anticholinergics in overactive bladder // Eur. Urol. – 2007. – Vol. 6. – N. 5. – Suppl. 7. – P. 425-431.
18. Wong S.H., Lau W.J., Poon G.P. The surgical management of nonfunctional tuberculous kidneys // J. Urol. (Baltimore). – 1984. – Vol. 131. – N. 2. – P. 297-301.
Review
For citations:
Tyllashaykhov M.N., Rashidov Z.R., Alydzhanov S.K. BOTULINUM TOXIN-A – THE EXPERIENCE OF UROLOGICAL TUBERCULOSIS PATIENTS TREATMENT. Tuberculosis and socially significant diseases. 2016;(1):42-45. (In Russ.)